Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the worlds largest independent biotechnology companies, Amgen was established in Thousand Oaks, California, in 1980.
Company profile
Ticker
AMGN
Exchange
Website
CEO
Robert Bradway
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
AMGEN
SEC CIK
Corporate docs
Subsidiaries
Amgen (Europe) GmbH • Amgen Australia Pty Ltd • Amgen Canada Inc. • Amgen Fremont Inc. • Amgen Global Finance B.V. • Amgen Global Manufacturing Ltd. • Amgen Global Technology Unlimited Company • Amgen GmbH • Amgen Ilaç Ticaret Limited • Amgen International Holdings Inc. ...
IRS number
953540776
AMGN stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
3 Jun 24
DEFA14A
Additional proxy soliciting materials
10 May 24
DEFA14A
Additional proxy soliciting materials
3 May 24
10-Q
2024 Q1
Quarterly report
2 May 24
8-K
Amgen Reports First Quarter 2024 Financial Results
2 May 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEFA14A
Additional proxy soliciting materials
17 Apr 24
DEF 14A
Definitive proxy
17 Apr 24
ARS
2023 FY
Annual report to shareholders
10 Apr 24
10-K
2023 FY
Annual report
14 Feb 24
Transcripts
AMGN
Earnings call transcript
2024 Q1
2 May 24
AMGN
Earnings call transcript
2023 Q4
6 Feb 24
AMGN
Earnings call transcript
2023 Q3
31 Oct 23
AMGN
Earnings call transcript
2023 Q2
3 Aug 23
AMGN
Earnings call transcript
2023 Q2
3 Aug 23
AMGN
Earnings call transcript
2023 Q1
27 Apr 23
AMGN
Earnings call transcript
2022 Q4
31 Jan 23
AMGN
Earnings call transcript
2022 Q3
4 Nov 22
AMGN
Earnings call transcript
2022 Q2
5 Aug 22
AMGN
Earnings call transcript
2022 Q1
28 Apr 22
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 9.71 bn | 9.71 bn | 9.71 bn | 9.71 bn | 9.71 bn | 9.71 bn |
Cash burn (monthly) | 412.00 mm | 1.82 bn | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 925.17 mm | 4.09 bn | n/a | n/a | n/a | n/a |
Cash remaining | 8.78 bn | 5.62 bn | n/a | n/a | n/a | n/a |
Runway (months of cash) | 21.3 | 3.1 | n/a | n/a | n/a | n/a |
Institutional ownership, Q1 2024
70.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2581 |
Opened positions | 464 |
Closed positions | 205 |
Increased positions | 939 |
Reduced positions | 841 |
13F shares | Current |
---|---|
Total value | 100.33 tn |
Total shares | 375.43 mm |
Total puts | 6.58 mm |
Total calls | 6.48 mm |
Total put/call ratio | 1.0 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 52.09 mm | $14.81 tn |
BLK Blackrock | 47.97 mm | $13.64 tn |
STT State Street | 29.13 mm | $8.28 tn |
MS Morgan Stanley | 13.97 mm | $3.97 tn |
Geode Capital Management | 11.64 mm | $3.30 tn |
WFC Wells Fargo & Co. | 7.50 mm | $2.13 tn |
Capital International Investors | 7.01 mm | $1.99 tn |
NTRS Northern Trust | 6.02 mm | $1.71 tn |
Capital Research Global Investors | 5.67 mm | $1.61 tn |
RY Royal Bank Of Canada | 5.46 mm | $1.55 tn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
31 May 24 | Austin Wanda M | Common Stock | Grant | Acquire A | No | No | 0 | 719 | 0.00 | 6,544 |
31 May 24 | Michael V Drake | Common Stock | Grant | Acquire A | No | No | 0 | 719 | 0.00 | 3,174.766 |
31 May 24 | Druker Brian | Common Stock | Grant | Acquire A | No | No | 0 | 719 | 0.00 | 6,472 |
31 May 24 | Eckert Robert | Common Stock | Grant | Acquire A | No | No | 0 | 719 | 0.00 | 23,715 |
News
Market Whales and Their Recent Bets on AMGN Options
6 Jun 24
Amgen Seeks Expanded US Approval For Autoimmune Disease Drug Acquired Via $28B Horizon Deal
5 Jun 24
Here's How Much You Would Have Made Owning Amgen Stock In The Last 20 Years
31 May 24
Amgen Secures FDA Nod For Rare-Disease Treatment Biosimilar Based On AstraZeneca's Drug
29 May 24
What's Going On With Mid-Cap Cancer-Focused Verastem Oncology Stock On Friday?
24 May 24
Press releases
AMGEN TO PRESENT AT GOLDMAN SACHS 45TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
5 Jun 24
AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE
3 Jun 24
AMGEN TO PRESENT INNOVATIVE RESEARCH FROM ITS ROBUST ONCOLOGY PORTFOLIO AT ASCO 2024
28 May 24
Emerging Trends in Oncology: ASCO 2024 Highlights Next-Gen Antibody-Drug Conjugates and More
24 May 24
NEW DATA PRESENTED AT ATS 2024 SHOW THE POTENTIAL OF TEZSPIRE® TO HELP PATIENTS LIVING WITH COPD
19 May 24